Table 2.
Lipid peroxidation markers in CAD patients without cognitive impairment (CAD controls) and those with cognitive impairment (VaMCI group). Sex, VO2 peak, BMI, and years of education added as covariates
| CAD controls | VaMCI | Sig | |||||
| (n = 89) | (n = 29) | ||||||
| Raw data | Mean | SD | Mean | SD | F/ x2 | df | p |
| LPH (μM) | 44.9 | 31.4 | 31.1 | 28.1 | 3.983 | 5 | 0.049 |
| 8-ISO (pg/mL) | 35 | 23.4 | 27.1 | 14.1 | 1.716 | 5 | 0.193 |
| 4-HNE (fmol/μg) | 40.7 | 9.3 | 40.0 | 7.3 | 0.054 | 5 | 0.817 |
| 8-ISO/LPH | 1.9 | 5.5 | 5.1 | 10.0 | 5.965 | 5 | 0.016 |
| 4-HNE/LPH | 2.4 | 5.5 | 7.3 | 14.8 | 8.278 | 5 | 0.005 |
| (8-ISO+4-HNE)/LPH | 0.5 | 0.1 | 0.4 | 0.1 | 6.629 | 5 | 0.011 |
| Log-transformed data | |||||||
| LPH (μM) | 1.5 | 0.4 | 1.2 | 0.6 | 8.913 | 5 | 0.004 |
| 8-ISO (pg/mL) | 1.4 | 0.3 | 1.4 | 0.3 | 0.698 | 5 | 0.405 |
| 4-HNE (fmol/μg) | 1.6 | 0.1 | 1.6 | 0.1 | 0.001 | 5 | 0.975 |
| 8-ISO/LPH | –0.1 | 0.5 | 0.2 | 0.7 | 4.145 | 5 | 0.004 |
| 4-HNE/LPH | 0.1 | 0.4 | 0.4 | 0.6 | 8.599 | 5 | 0.004 |
| (8-ISO+4-HNE)/LPH | 0.3 | 0.4 | 0.6 | 0.6 | 7.022 | 5 | 0.009 |